<110>  Precision Biologics, Inc.
       Wang, Xue-Ping


<120> HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE FOR THE 
DIAGNOSIS AND TREATMENT OF COLON AND PANCREAS CANCER


<130>  43282.3013

<141>  2013-12-30

<150>  61/747,067
<151>  2012-12-28

<160>  94

<170>  PatentIn version 3.5

<210>  1
<211>  307 
<212>  PRT 
<213>  Artificial Sequence

<220>
<223>  NPC-1 antigen (variant 1)

<400>  1

Thr Thr His Ser Gln Pro Val Thr Arg Asp Cys His Leu Arg Cys Thr
1               5                   10                  15


Trp Thr Lys Trp Phe Asp Val Asp Phe Pro Ser Pro Gly Pro His Gly
            20                  25                  30


Gly Asp Lys Glu Thr Tyr Asn Asn Ile Ile Arg Ser Gly Glu Lys Ile
        35                  40                  45


Cys Arg Arg Pro Glu Glu Ile Thr Arg Leu Gln Cys Arg Ala Glu Ser
    50                  55                  60


His Pro Glu Val Ser Ile Glu His Leu Gly Gln Val Val Gln Cys Ser
65                  70                  75                  80


Arg Glu Glu Gly Leu Val Cys Arg Asn Gln Asp Gln Gln Gly Pro Phe
                85                  90                  95


Lys Met Cys Leu Asn Tyr Glu Val Arg Val Leu Cys Cys Glu Thr Pro
            100                 105                 110


Lys Gly Cys Pro Val Thr Ser Thr Pro Val Thr Ala Pro Ser Thr Pro
        115                 120                 125


Ser Gly Arg Ala Thr Ser Pro Thr Gln Ser Thr Ser Ser Trp Gln Lys
    130                 135                 140


Ser Arg Thr Thr Thr Leu Val Thr Thr Ser Thr Thr Ser Thr Pro Gln
145                 150                 155                 160


Thr Ser Thr Thr Ser Ala Pro Thr Thr Ser Thr Thr Ser Ala Pro Thr
                165                 170                 175


Thr Ser Thr Thr Ser Ala Pro Thr Thr Ser Thr Thr Ser Thr Pro Gln
            180                 185                 190


Thr Ser Ile Ser Ser Ala Pro Thr Ser Ser Thr Thr Ser Ala Pro Thr
        195                 200                 205


Ser Ser Thr Ile Ser Ala Arg Thr Thr Ser Ile Ile Ser Ala Pro Thr
    210                 215                 220


Thr Ser Thr Thr Ser Ser Pro Thr Thr Ser Thr Thr Ser Ala Thr Thr
225                 230                 235                 240


Thr Ser Thr Thr Ser Ala Pro Thr Ser Ser Thr Thr Ser Thr Pro Gln
                245                 250                 255


Thr Ser Lys Thr Ser Ala Ala Thr Ser Ser Thr Thr Ser Ser Ser Gly
            260                 265                 270


Thr Thr Pro Ser Pro Val Thr Thr Thr Ser Thr Ala Ser Val Ser Lys
        275                 280                 285


Thr Ser Thr Ser His Val Ser Val Ser Lys Thr Thr His Ser Gln Pro
    290                 295                 300


Val Thr Arg
305


<210>  2
<211>  281 
<212>  PRT 
<213>  Artificial Sequence

<220>
<223>  NPC-1 antigen (variant 2)

<400>  2

Gly Thr His Thr Thr Pro Val Thr Arg Asn Cys His Pro Arg Cys Thr
1               5                   10                  15


Trp Thr Lys Trp Phe Asp Val Asp Phe Pro Ser Pro Gly Pro His Gly
            20                  25                  30


Gly Asp Lys Glu Thr Tyr Asn Asn Ile Ile Arg Ser Gly Glu Lys Ile
        35                  40                  45


Cys Arg Arg Pro Glu Glu Ile Thr Arg Leu Gln Cys Arg Ala Lys Ser
    50                  55                  60


His Pro Glu Val Ser Ile Glu His Leu Gly Gln Val Val Gln Cys Ser
65                  70                  75                  80


Arg Glu Glu Gly Leu Val Cys Arg Asn Gln Asp Gln Gln Gly Pro Phe
                85                  90                 95


Lys Met Cys Leu Asn Tyr Glu Val Arg Val Leu Cys Cys Glu Thr Pro
            100                 105                 110


Arg Gly Cys Pro Val Thr Ser Thr Pro Val Thr Ala Pro Ser Thr Pro
        115                 120                 125


Ser Gly Arg Ala Ile Ser Pro Thr Gln Ser Thr Ser Ser Trp Gln Lys
    130                 135                 140


Ser Arg Thr Thr Thr Leu Val Thr Thr Ser Thr Thr Ser Thr Pro Gln
145                 150                 155                 160

Thr Ser Thr Thr Tyr Ala His Thr Thr Ser Thr Thr Ser Ala Pro Thr
                165                 170                 175


Ala Arg Thr Thr Ser Ala Pro Thr Thr Arg Thr Thr Ser Ala Ser Pro
            180                 185                 190


Ala Ser Thr Thr Ser Gly Pro Gly Asn Thr Pro Ser Pro Val Pro Thr
        195                 200                 205


Thr Ser Thr Ile Ser Ala Pro Thr Thr Ser Ile Thr Ser Ala Pro Thr
    210                 215                 220


Thr Ser Thr Thr Ser Ala Pro Thr Ser Ser Thr Thr Ser Ala Pro Thr
225                 230                 235                 240


Thr Ser Thr Thr Ser Ala Pro Thr Ser Ser Thr Thr Ser Ser Pro Gln
                245                 250                 255


Thr Ser Thr Thr Ser Ala Pro Thr Thr Ser Thr Thr Ser Gly Pro Gly
            260                 265                 270


Thr Thr Pro Ser Pro Val Pro Thr Thr
        275                 280


<210>  3
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MUC5AC NPC-1 epitope (1)

<400>  3

Thr Thr Ser Thr Thr Ser Ala Pro Thr Thr Ser Thr Thr Ser Ala Pro
1               5                   10                  15


<210>  4
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MUC5AC NPC-1 epitope (2)

<400>  4

Gly Cys Pro Val Thr Ser Thr Pro Val Thr Ala Pro Ser Thr Pro
1               5                   10                  15



<210>  5
<211>  92
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CEACAM5 16C3 epitope


<220>
<221>  MISC_FEATURE
<222>  (8)..(67)
<223>  Xaa can be any amino acid

<400>  5

Gly Pro Asp Ala Pro Thr Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1               5                   10                  15


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
            20                  25                  30


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
        35                  40                  45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
    50                  55                  60


Xaa Xaa Xaa Gly Ser Tyr Thr Cys Gln Ala His Asn Ser Asp Thr Gly
65                  70                  75                  80


Leu Asn Arg Thr Thr Val Thr Thr Ile Thr Val Tyr
                85                  90


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CEACAM 16C3 epitope N-terminal flanking peptide

<400>  6

Gly Pro Asp Ala Pro Thr Ile
1               5


<210>  7
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CEACAM5 16C3 C-terminal flanking peptide

<400>  7

Gly Ser Tyr Thr Cys Gln Ala His Asn Ser Asp Thr Gly Leu Asn Arg
1               5                   10                  15


Thr Thr Val Thr Thr Ile Thr Val Tyr
            20                  25


<210>  8
<211>  92
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CEACAM6 16C3 epitope


<220>
<221>  MISC_FEATURE
<222>  (8)..(67)
<223>  Xaa can be any amino acid

<400> 8

Gly Pro Asp Gly Pro Thr Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1               5                   10                  15


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
            20                  25                  30


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
        35                  40                  45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
    50                  55                  60


Xaa Xaa Xaa Gly Ser Tyr Met Cys Gln Ala His Asn Ser Ala Thr Gly
65                  70                  75                  80


Leu Asn Arg Thr Thr Val Thr Met Ile Thr Val Ser
                85                  90


<210>  9
<211>  25
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CEACAM6 C-terminal flanking peptide

<400>  9

Gly Ser Tyr Met Cys Gln Ala His Asn Ser Ala Thr Gly Leu Asn Arg
1               5                   10                  15

Thr Thr Val Thr Met Ile Thr Val Ser
            20                  25


<210>  10
<211>  319
<212>  PRT
<213>  Homo sapiens

<220>
<223>  A33 antigen


<400>  10

Met Val Gly Lys Met Trp Pro Val Leu Trp Thr Leu Cys Ala Val Arg
1               5                   10                  15


Val Thr Val Asp Ala Ile Ser Val Glu Thr Pro Gln Asp Val Leu Arg
            20                  25                  30

Ala Ser Gln Gly Lys Ser Val Thr Leu Pro Cys Thr Tyr His Thr Ser
        35                  40                  45


Thr Ser Ser Arg Glu Gly Leu Ile Gln Trp Asp Lys Leu Leu Leu Thr
    50                  55                  60


His Thr Glu Arg Val Val Ile Trp Pro Phe Ser Asn Lys Asn Tyr Ile
65                  70                  75                  80


His Gly Glu Leu Tyr Lys Asn Arg Val Ser Ile Ser Asn Asn Ala Glu
                85                  90                  95


Gln Ser Asp Ala Ser Ile Thr Ile Asp Gln Leu Thr Met Ala Asp Asn
            100                 105                 110


Gly Thr Tyr Glu Cys Ser Val Ser Leu Met Ser Asp Leu Glu Gly Asn
        115                 120                 125


Thr Lys Ser Arg Val Arg Leu Leu Val Leu Val Pro Pro Ser Lys Pro
    130                 135                 140


Glu Cys Gly Ile Glu Gly Glu Thr Ile Ile Gly Asn Asn Ile Gln Leu
145                 150                 155                 160


Thr Cys Gln Ser Lys Glu Gly Ser Pro Thr Pro Gln Tyr Ser Trp Lys
                165                 170                 175


Arg Tyr Asn Ile Leu Asn Gln Glu Gln Pro Leu Ala Gln Pro Ala Ser
            180                 185                 190


Gly Gln Pro Val Ser Leu Lys Asn Ile Ser Thr Asp Thr Ser Gly Tyr
        195                 200                 205


Tyr Ile Cys Thr Ser Ser Asn Glu Glu Gly Thr Gln Phe Cys Asn Ile
    210                 215                 220


Thr Val Ala Val Arg Ser Pro Ser Met Asn Val Ala Leu Tyr Val Gly
225                 230                 235                 240


Ile Ala Val Gly Val Val Ala Ala Leu Ile Ile Ile Gly Ile Ile Ile
                245                 250                 255


Tyr Cys Cys Cys Cys Arg Gly Lys Asp Asp Asn Thr Glu Asp Lys Glu
            260                 265                 270


Asp Ala Arg Pro Asn Arg Glu Ala Tyr Glu Glu Pro Pro Glu Gln Leu
        275                 280                 285


Arg Glu Leu Ser Arg Glu Arg Glu Glu Glu Asp Asp Tyr Arg Gln Glu
    290                 295                 300


Glu Gln Arg Ser Thr Gly Arg Glu Ser Pro Asp His Leu Asp Gln
305                 310                 315


<210>  11
<211>  56
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A33 antigen mass spec fragment 1

<400>  11

Ala Ser Gln Gly Lys Ser Val Thr Leu Pro Cys Thr Tyr His Thr Ser
1               5                   10                  15


Thr Ser Ser Arg Glu Gly Leu Ile Gln Trp Asp Lys Leu Leu Leu Thr
            20                  25                  30


His Thr Glu Arg Val Val Ile Trp Pro Phe Ser Asn Lys Asn Tyr Ile
        35                  40                  45


His Gly Glu Leu Tyr Lys Asn Arg
    50                  55


<210>  12
<211>  67
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A33 antigen mass spec fragment 2

<400>  12

Val Arg Leu Leu Val Leu Val Pro Pro Ser Lys Pro Glu Cys Gly Ile
1               5                   10                  15


Glu Gly Glu Thr Ile Ile Gly Asn Asn Ile Gln Leu Thr Cys Gln Ser
            20                  25                  30


Lys Glu Gly Ser Pro Thr Pro Gln Tyr Ser Trp Lys Arg Tyr Asn Ile
        35                  40                  45


Leu Asn Gln Glu Gln Pro Leu Ala Gln Pro Ala Ser Gly Gln Pro Val
    50                  55                  60


Ser Leu Lys
65


<210>  13
<211>  55
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  A33 antigen mass spec fragment 3

<400>  13

Asp Asp Asn Thr Glu Asp Lys Glu Asp Ala Arg Pro Asn Arg Glu Ala
1               5                   10                  15


Tyr Glu Glu Pro Pro Glu Gln Leu Arg Glu Leu Ser Arg Glu Arg Glu
            20                  25                  30


Glu Glu Asp Asp Tyr Arg Gln Glu Glu Gln Arg Ser Thr Gly Arg Glu
        35                  40                  45


Ser Pro Asp His Leu Asp Gln
    50                  55


<210>  14
<211>  965
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NPC-1 antibody light chain

<400>  14
atgagaatac cattaattag ctagggacca aaattcaaag acaaaatgga ttttcaggtg      60

cagattttca gcttcctgct aatcagtgcc tcagtcatac tgtccagagg acaagttgtt     120

ctcacccagt ctccagtaat catgtctgca tctccagggg agaaggtcac catgacctgc     180

agtgccagct caagtataag ttacatgtac tggtaccagc agaagccagg cacctccccc     240

aaaagatgga tttatgacac atccaaactg gcttctggag tccctgctcg cttcagtggc     300

agtgggtctg ggacctctta ttctctcaca atcagcaaca tggaggctgg agatgctgcc     360

acttattact gccatcagcg ggattcttac ccatggacgt tcggtggagg caccaacctg     420

gaaatcaaac gggctgatgc tgcaccaact gtatccatct tcccaccatc cagtgagcag     480

ttaacatctg gaggtgcctc agtcgtgtgc ttcttgaaca acttctaccc caaagacatc     540

aatgtcaagt ggaagattga tggcagtgaa cgacaaaatg gcgtcctgaa cagttggact     600

gatcaggaca gcaaagacag cacctacagc atgagcagca ccctcacgtt gaccaaggac     660

gagtatgaac gacataacag ctatacctgt gaggccactc acaagacatc aacttcaccc     720

attgtcaaga gcttcaacag gaatgagtgt tagagacaaa ggtcctgaga cgccaccacc     780

agctccccag ctccatccta tcttcccttc taaggtcttg gaggcttccc cacaagcgac     840

ctaccactgt tgcggtgctc caaacctcct ccccacctcc ttctcctcct cctccctttc     900

cttggctttt atcatgctaa tatttgcaga aaatattcaa taaagtgagt ctttgcactt     960

gaaaa                                                                 965


<210>  15
<211>  235
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 antibody light chain


<220>
<221>  MISC_FEATURE
<222>  (46)..(55)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (71)..(77) 
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (110)..(118) 
<223>  CDR3

<400>  15

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1               5                   10                  15


Val Ile Leu Ser Arg Gly Gln Val Val Leu Thr Gln Ser Pro Val Ile
            20                  25                  30


Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser
        35                  40                  45


Ser Ser Ile Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Thr Ser
    50                  55                  60


Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro
65                  70                  75                  80


Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
                85                  90                  95


Ser Asn Met Glu Ala Gly Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg
            100                 105                 110


Asp Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys
        115                 120                 125


Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
    130                 135                 140


Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
145                 150                 155                 160


Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
                165                 170                 175


Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
            180                 185                 190


Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
        195                 200                 205


Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
    210                 215                 220


Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
225                 230                 235


<210>  16
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 light chain CDR1

<400>  16

Ser Ala Ser Ser Ser Ile Ser Tyr Met Tyr
1               5                   10


<210>  17
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 light chain CDR2

<400>  17

Asp Thr Ser Lys Leu Ala Ser
1               5


<210>  18
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 antibody light chain CDR3

<400>  18

His Gln Arg Asp Ser Tyr Pro Trp Thr 
1               5


<210>  19
<211>  1520
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NPC-1 antibody heavy chain

<400> 19
ttttccatcc tcttctcata gagcctccat cagaccatgg ctgtcctggc actgctcctc      60

tgcctggtga cattcccaag ctgtgtcctg tcccaggtgc agctgaagga gtcaggacct     120

gacctggtgg cgccctcaca gagcctgtcc atcacatgca ctgtctcagg attctcatta     180

agcaaatttg gtgtaaactg ggttcgccag cctccaggaa agggtctgga gtggctggga     240

gtaatatggg gtgacgggag cacaagttat aattcaggtc tcatatcaag actgagcatc     300

agcaaggaga actccaagag ccaggttttc ttaaaactga acagtctgca agctgatgac     360

acagccacat actactgtgt caaaccgggg ggtgactact ggggtcacgg aacctcagtc     420

accgtctcct cagccaaaac gacaccccca tctgtctatc cactggcccc tggatctgct     480

gcccaaacta actccatggt gaccctggga tgcctggtca agggctattt ccctgagcca     540

gtgacagtga cctggaactc tggatccctg tccagcggtg tgcacacctt cccagctgtc     600

ctgcagtctg acctctacac tctgagcagc tcagtgactg tcccctccag cacctggccc     660

agcgagaccg tcacctgcaa cgttgcccac ccggccagca gcaccaaggt ggacaagaaa     720

attgtgccca gggattgtgg ttgtaagcct tgcatatgta cagtcccaga agtatcatct     780

gtcttcatct tccccccaaa gcccaaggat gtgctcacca ttactctgac tcctaaggtc     840

acgtgtgttg tggtagacat cagcaaggat gatcccgagg tccagttcag ctggtttgta     900

gatgtggagg tgcacacagc tcagacgcaa ccccgggagg agcagttcaa cagcactttc     960

cgctcagtca gtgaacttcc catcatgcac caggactggc tcaatggcaa ggagttcaaa    1020

tgcagggtca acagtgcagc tttccctgcc cccatcgaga aaaccatctc caaaaccaaa    1080

ggcagaccga aggctccaca ggtgtacacc attccacctc ccaaggagca gatggccaag    1140

gataaagtca gtctgacctg catgataaca gacttcttcc ctgaagacat tactgtggag    1200

tggcagtgga atgggcagcc agcggagaac tacaagaaca ctcagcccat catggacaca    1260

gatggctctt acttcgtcta cagcaagctc aatgtgcaga agagcaactg ggaggcagga    1320

aatactttca cctgctctgt gttacatgag ggcctgcaca accaccatac tgagaagagc    1380

ctctcccact ctcctggtaa atgatcccag tgtccttgga gccctctggt cctacaggac    1440

tctgacacct acctccaccc ctccctgtat aaataaagca cccagcactg ccttgggacc    1500

ctgcaaaaaa aaaaaaaaaa                                                1520


<210>  20
<211>  456
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 antibody heavy chain


<220>
<221>  MISC_FEATURE
<222>  (49)..(54) 
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (69)..(84)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (114)..(121)
<223>  CDR3

<400>  20

Met Ala Val Leu Ala Leu Leu Leu Cys Leu Val Thr Phe Pro Ser Cys
1               5                   10                  15


Val Leu Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Asp Leu Val Ala
            20                  25                  30


Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu
        35                  40                  45


Ser Lys Phe Gly Val Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu
    50                  55                  60


Glu Trp Leu Gly Val Ile Trp Gly Asp Gly Ser Thr Ser Tyr Asn Ser
65                  70                  75                  80


Gly Leu Ile Ser Arg Leu Ser Ile Ser Lys Glu Asn Ser Lys Ser Gln
                85                  90                  95


Val Phe Leu Lys Leu Asn Ser Leu Gln Ala Asp Asp Thr Ala Thr Tyr
            100                 105                110


Tyr Cys Val Lys Pro Gly Gly Asp Tyr Trp Gly His Gly Thr Ser Val
        115                 120                 125


Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala
    130                 135                 140


Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu
145                 150                 155                 160


Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly
                165                 170                 175


Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp
            180                 185                 190


Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro
        195                 200                 205


Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys
    210                 215                 220


Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile
225                 230                 235                 240


Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro
                245                 250                 255


Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val
            260                 265                 270


Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val
        275                 280                 285


Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln
    290                 295                 300


Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln
305                 310                 315                 320


Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala
                325                 330                 335


Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro
            340                 345                 350


Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala
        355                 360                 365


Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu
    370                 375                 380


Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr
385                 390                 395                 400


Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr
                405                 410                 415


Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe
            420                 425                 430


Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys
        435                 440                 445


Ser Leu Ser His Ser Pro Gly Lys
    450                 455


<210>  21
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 antibody heavy chain CDR1

<400>  21

Ser Lys Phe Gly Val Asn
1               5


<210>  22
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 heavy chain CDR2

<400>  22

Val Ile Trp Gly Asp Gly Ser Thr Ser Tyr Asn Ser Gly Leu Ile Ser
1               5                   10                  15


<210>  23
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 antibody heavy chain CDR3

<400> 23

Cys Val Lys Pro Gly Gly Asp Tyr
1               5


<210>  24
<211>  737
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NPC-1 Chi-antibody light chain

<400>  24
gcatagatct gccaccatgg actttcaggt ccagatattt agctttctat tgattagcgc      60

ctctgtcatt ctgagtaggg ggcaggtggt gctcacccag tctccagtga tcatgtcagc     120

ctcaccagga gaaaaagtga ctatgacctg ctcagcatcc tccagcatca gttacatgta     180

ctggtaccag cagaagccag gcacctcgcc caagcgttgg atctacgata cttccaagct     240

ggcaagtggg gtacccgcac gcttcagtgg aagtggctcc ggaacctcgt acagtttgac     300

catttcaaat atggaagctg gggacgcagc tacatattat tgccaccaga gagactccta     360

cccgtggacc ttcggaggcg gtactaattt agagatcaag aggaccgtag ccgctccttc     420

cgtgttcatc tttccccctt ccgacgaaca actgaaaagc ggtacagcct ccgtggtttg     480

tctgctgaac aacttctacc cccgggaggc taaagttcag tggaaggttg acaatgctct     540

gcagtcaggc aactctcaag agagcgtcac ggagcaagat agcaaagatt ctacatattc     600

tctctcttct acacttacac ttagcaaggc cgattatgag aagcacaagg tgtatgcctg     660

cgaggtgact catcagggtc tttcttctcc tgtcactaaa agcttcaacc gaggcgaatg     720

ttgatgaaga tcttacg                                                    737


<210>  25
<211>  235
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody light chain with signal peptide


<220>
<221>  SIGNAL
<222>  (1)..(22)

<220>
<221>  MISC_FEATURE
<222>  (46)..(55)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (71)..(77)
<223>  CDR2

<220>
<221>  MISC_FEATURE 
<222>  (110)..(118)
<223>  CDR3

<400>  25

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1               5                   10                  15


Val Ile Leu Ser Arg Gly Gln Val Val Leu Thr Gln Ser Pro Val Ile
            20                  25                  30

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser
        35                  40                  45


Ser Ser Ile Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Thr Ser
    50                  55                  60


Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro
65                  70                  75                  80


Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
                85                  90                  95


Ser Asn Met Glu Ala Gly Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg
            100                 105                 110


Asp Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys
        115                 120                 125


Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
    130                 135                 140


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
145                 150                 155                 160


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
                165                 170                 175


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
            180                 185                 190


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
        195                 200                 205


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
    210                 215                 220


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225                 230                 235


<210>  26
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody light chain CDR1

<400>  26

Ser Ala Ser Ser Ser Ile Ser Tyr Met Tyr
1               5                   10


<210>  27
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody light chain CDR2

<400>  27

Asp Thr Ser Lys Leu Ala Ser
1               5


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody light chain CDR3

<400> 28

His Gln Arg Asp Ser Tyr Pro Trp Thr
1               5


<210>  29
<211>  1418
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody heavy chain

<400>  29
gagcggtacc gccaccatgg cagtgctggc ccttcttcta tgtctggtga ccttcccatc      60

ctgcgtcctg agccaggtac aactgaagga gtcgggccca gacctagtgg ctccgtcaca     120

atcactctcc attacgtgca ctgtctccgg cttctctttg tctaaattcg gcgtgaattg     180

ggtgcgacag ccccccggga aggggcttga gtggttagga gttatctggg gtgacggctc     240

aaccagctac aactcaggac taatctcacg cttgtcaatt tcaaaggaga attcaaagtc     300

tcaggtgttc cttaagctca actcgctgca agccgacgat accgcaacct attactgcgt     360

caaacctggc ggggactact ggggccatgg cacctccgtc acagtgagtt ccgcatccac     420

aaagggtccc agtgtttttc ctttggcgcc ctctagcaaa tcgacatctg gcggcacagc     480

cgcacttggg tgcttggtta aagactactt ccccgaaccg gtgacagtat cttggaactc     540

tggcgctctt accagcggag ttcatacctt ccctgccgta ttacagtcta gcgggcccta     600

ctccctctcc tctgtcgtga cagtcccaag ctcttctctg ggaactcaaa cctacatctg     660

caatgtgaac cataaaccta gcaacacgaa agtggacaaa aaggtcgaac ccaagagttg     720

cgacaagaca cacacctgcc ctccttgtcc tgctccagag ctcctcggcg gacctagcgt     780

tttcttgttc cctccgaaac caaaggacac cttgatgatt tctcggaccc ccgaggtgac     840

atgtgtagta gttgatgtct cccacgagga ccctgaggtc aagtttaatt ggtatgtgga     900

cggtgtggag gtccacaacg ccaaaacaaa accacgggag gaacagtaca attccacata     960

tagggtggtg agcgtcctta ccgtcctgca tcaggattgg ttaaatggta aggagtataa    1020

gtgtaaggtg tctaacaagg ctctgcctgc tcccatcgaa aaaactataa gtaaggccaa    1080

aggacagccc agggaacctc aggtgtatac tcttccaccc agtagagatg agctgactaa    1140

aaaccaggtg tccctgactt gtctggtgaa gggattttac ccatccgata tcgccgtgga    1200

atgggagtcc aacggacagc cagaaaacaa ttataaaact atgccaccag tgctggatag    1260

tgatggtagt ttttttctgt acagtaagct gactgttgat aagagtagat ggcagcaggg    1320

taatgttttt agttgtagcg ttatgcacga agctctgcac aatcactata ctcagaagag    1380

cctgagcctg agccccggta agtgatgagg taccgagc                            1418


<210>  30
<211>  462
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody heavy chain


<220>
<221>  SIGNAL
<222>  (1)..(19)

<400>  30

Met Ala Val Leu Ala Leu Leu Leu Cys Leu Val Thr Phe Pro Ser Cys
1               5                   10                  15


Val Leu Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Asp Leu Val Ala
            20                  25                  30


Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu
        35                  40                  45


Ser Lys Phe Gly Val Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu
    50                  55                  60


Glu Trp Leu Gly Val Ile Trp Gly Asp Gly Ser Thr Ser Tyr Asn Ser
65                  70                  75                  80


Gly Leu Ile Ser Arg Leu Ser Ile Ser Lys Glu Asn Ser Lys Ser Gln
                85                  90                  95


Val Phe Leu Lys Leu Asn Ser Leu Gln Ala Asp Asp Thr Ala Thr Tyr
            100                 105                 110


Tyr Cys Val Lys Pro Gly Gly Asp Tyr Trp Gly His Gly Thr Ser Val
        115                 120                 125


Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
    130                 135                 140


Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
145                 150                 155                 160


Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
                165                 170                 175


Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
            180                 185                 190


Gly Pro Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
        195                 200                 205


Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
    210                 215                 220


Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
225                 230                 235                 240


Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
                245                 250                 255


Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
            260                 265                 270


Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
        275                 280                 285


Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
    290                 295                 300


Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
305                 310                 315                 320


Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
                325                 330                 335


Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
            340                 345                 350


Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
        355                 360                 365


Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
    370                 375                 380


Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
385                 390                 395                 400


Gln Pro Glu Asn Asn Tyr Lys Thr Met Pro Pro Val Leu Asp Ser Asp
                405                 410                 415


Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
            420                 425                 430


Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
        435                 440                 445


Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
    450                 455                 460


<210>  31
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody heavy chain CDR1

<400>  31

Gly Phe Ser Leu Ser Lys Phe Gly Val Asn
1               5                   10


<210>  32
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody heavy chain CDR2

<400>  32

Val Ile Trp Gly Asp Gly Ser Thr Ser Tyr Asn Ser Gly Leu Ile Ser
1               5                   10                  15


<210>  33
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NPC-1 chi-antibody heavy chain CDR3

<400>  33

Pro Gly Gly Asp Tyr
1               5


<210>  34
<211>  735
<212>  DNA
<213> Artificial Sequence

<220>
<223> Humanized NEO 103 light chain

<400> 34
aagcttgcca ccatgaagta cctgctgccc accgctgctg ctggcttgct gctgctggca      60

gctcagcctg ccatggccga gatcgtgctg acccagtctc ctggcaccct gtctctgagc     120

cctggcgaga gagctaccct gtcctgctcc gcctcctcca gcatctccta catgtactgg     180

tatcagcaga agcccggcca ggcccctcgg ctgctgatct acgatacctc caagctggcc     240

tccggcatcc ccgacagatt ctccggctct ggctctggca ccgacttcac cctgaccatc     300

tcccggctgg aacccgagga cttcgccgtg tactactgcc accagcggga ctcctacccc     360

tggacctttg gccagggcac caagctggaa atcaagcgga ccgtggccgc tccctccgtg     420

ttcatcttcc caccttccga cgagcagctg aagtccggca ccgcttctgt cgtgtgcctg     480

ctgaacaact tctacccccg cgaggccaag gtgcagtgga aggtggacaa cgccctgcag     540

tccggcaact cccaggaatc cgtgaccgag caggactcca aggacagcac ctactccctg     600

tcctctaccc tgaccctgtc caaggccgac tacgagaagc acaaggtgta cgcctgcgaa     660

gtgacccacc agggcctgtc tagccccgtg accaagtctt tcaaccgggg cgagtgctga     720

tgaggatcct gatga                                                      735


<210>  35
<211>  239
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized NEO 103 light chain

<400>  35

Lys Leu Ala Thr Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu
1               5                   10                  15


Leu Leu Leu Ala Ala Gln Pro Ala Met Ala Glu Ile Val Leu Thr Gln
            20                  25                  30


Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser
        35                  40                  45


Cys Ser Ala Ser Ser Ser Ile Ser Tyr Met Tyr Trp Tyr Gln Gln Lys
    50                  55                  60


Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Thr Ser Lys Leu Ala
65                  70                  75                  80


Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
                85                  90                  95


Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr
            100                 105                 110


Cys His Gln Arg Asp Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys
        115                 120                 125


Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
    130                 135                 140


Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
145                 150                 155                 160


Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp
                165                 170                 175


Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
            180                 185                 190


Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
        195                 200                 205


Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln
    210                 215                 220


Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225                 230                 235


<210>  36
<211>  1437
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Humanized NEO 103 heavy chain

<400>  36
aagcttgcca ccatggacct gctgtgcaag aacatgaagc acctgtggtt ctttctgctg      60

ctggtggccg ctcccagatg ggtgctgtct caggtgcagc tggtggaatc tggccctggc     120

ctggtgcagc cttccagatc cctgtctctg acctgctcct ccagcggctt cagcctgtcc     180

aagttcggcg tgaactgggt gcgacagcct cctggcaagg gcctggaatg ggtgggagtg     240

atctggggcg acggctccac ctcctacaac tccggcctga tctccagagt gaccatctcc     300

cgggacacct ccaagaacca gctgttcctg aagatggact ccctgaccgc cgaggacacc     360

gccgtgtact actgtgctag acctggcggc gactactggg gccagggcac aacagtgacc     420

gtgtcctccg cttccaccaa gggcccctct gtgtttcctc tggccccctc cagcaagtcc     480

acctctggtg gaactgccgc tctgggctgc ctcgtgaagg actacttccc cgagcccgtg     540

acagtgtcct ggaactctgg cgctctgacc tccggcgtgc acacctttcc agctgtgctg     600

cagtccagcg gcctgtactc cctgtcctcc gtcgtgaccg tgccttccag ctctctgggc     660

acccagacct acatctgcaa cgtgaaccac aagccctcca ataccaaggt ggacaagaag     720

gtggaaccca agtcctgcga caagacccac acctgtcccc cttgtcctgc ccctgaactg     780

ctgggcggac cttccgtgtt cctgttcccc ccaaagccca aggacaccct gatgatctcc     840

cggacccccg aagtgacctg cgtggtggtg gatgtgtccc acgaggaccc tgaagtgaag     900

ttcaattggt acgtggacgg cgtggaagtg cacaacgcca agaccaagcc tagagaggaa     960

cagtacaact ccacctaccg ggtggtgtcc gtgctgaccg tgctgcatca ggactggctg    1020

aacggcaaag agtacaagtg caaggtgtcc aacaaggccc tgcctgcccc catcgaaaag    1080

accatcagca aggctaaggg ccagccccgc gagccccagg tgtacacact gcctccatcc    1140

cgggaagaga tgaccaagaa tcaggtgtcc ctgacctgtc tcgtgaaagg cttctacccc    1200

tccgatatcg ccgtggaatg ggagtccaac ggccagcccg agaacaacta caagaccacc    1260

ccccctgtgc tggactccga cggctcattc ttcctgtaca gcaagctgac agtggacaag    1320

tcccggtggc agcagggcaa cgtgttctcc tgctccgtga tgcacgaggc cctgcacaac    1380

cactacaccc agaagtccct gtccctgagc cccggcaagt gatgatgagg atcctga       1437


<210>  37
<211>  473
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized NEO 103 heavy chain

<400>  37

Lys Leu Ala Thr Met Asp Leu Leu Cys Lys Asn Met Lys His Leu Trp
1               5                   10                  15


Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp Val Leu Ser Gln Val
            20                  25                  30


Gln Leu Val Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Arg Ser Leu
        35                  40                  45


Ser Leu Thr Cys Ser Ser Ser Gly Phe Ser Leu Ser Lys Phe Gly Val
    50                  55                  60


Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Gly Val
65                  70                  75                  80


Ile Trp Gly Asp Gly Ser Thr Ser Tyr Asn Ser Gly Leu Ile Ser Arg
                85                  90                  95


Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Leu Phe Leu Lys Met
            100                 105                 110


Asp Ser Leu Thr Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro
        115                 120                 125


Gly Gly Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala
    130                 135                 140


Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
145                 150                 155                 160


Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
                165                 170                 175


Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
            180                 185                 190


Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
        195                 200                 205


Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
    210                 215                 220


Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
225                 230                 235                 240


Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
                245                 250                 255


Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
            260                 265                 270


Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
        275                 280                 285


Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
    290                 295                 300


Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
305                 310                 315                 320


Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
                325                 330                 335


Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
            340                 345                 350


Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
        355                 360                 365


Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
    370                 375                 380


Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
385                 390                 395                 400


Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
                405                 410                 415


Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
            420                 425                 430


Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val

        435                 440                 445

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
    450                 455                 460


Lys Ser Leu Ser Leu Ser Pro Gly Lys
465                 470


<210>  38
<211>  963
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain

<400> 38
gcggggcagc ctcacacaga acacacacag atatgggtgt acccactcag ctcctgttgc      60

tgtggcttac agtcgtagtt gtcagatgtg acatccagat gactcagtct ccagcttcac     120

tgtctgcatc tgtgggagaa actgtcacca tcacatgtgg agcaagtgag aatatttacg     180

gtgctttaaa ttggtatcag cggaaacagg gaaaatctcc tcagctcctg atttatggcg     240

caagtaattt ggcagatggc atgtcatcga ggttcagtgg cagtggatct ggtagacagt     300

attctctcaa gatcagtagc ctgcatcctg acgatgttgc aacgtattac tgtcaaaatg     360

tattaagtag tccgtacacg ttcggagggg ggaccaagct ggaaataaaa cgggctgatg     420

ctgcaccaac tgtatccatc ttcccaccat ccagtgagca gttaacatct ggaggtgcct     480

cagtcgtgtg cttcttgaac aacttctacc ccaaagacat caatgtcaag tggaagattg     540

atggcagtga acgacaaaat ggcgtcctga acagttggac tgatcaggac agcaaagaca     600

gcacctacag catgagcagc accctcacgt tgaccaagga cgagtatgaa cgacataaca     660

gctatacctg tgaggccact cacaagacac caacttcacc cattgtcaag agcttcaaca     720

ggaatgagtg ttagagacaa aggtcctgag acgccaccac cagctcccca gctccatcct     780

atcttccctt ctaaggtctt ggaggcttcc ccacaagcga ctaccactgt tgcggtgctc     840

caaacctcct ccccacctcc ttctcctcct cctccctttc cttggctttt atcatgctaa     900

tatttgcaga aaatattcaa taaagtgatc tttgcacaaa aaaaaaaaaa aaaaaaaaaa     960

aaa                                                                   963


<210>  39
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain


<220>
<221>  MISC_FEATURE
<222>  (22)..(32)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (48)..(54)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (86)..(95)
<223>  CDR3

<400>  39

Leu Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr
1               5                   10                  15


Val Thr Ile Thr Cys Gly Ala Ser Glu Asn Ile Tyr Gly Ala Leu Asn
            20                  25                  30


Trp Tyr Gln Arg Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile Tyr Gly
        35                  40                  45


Ala Ser Asn Leu Ala Asp Gly Met Ser Ser Arg Phe Ser Gly Ser Gly
    50                  55                  60


Ser Gly Arg Gln Tyr Ser Leu Lys Ile Ser Ser Leu His Pro Asp Asp
65                  70                  75                  80


Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Ser Pro Tyr Thr Phe
                85                  90                  95


Gly Gly Gly Thr Lys Leu Glu Ile Lys Lys Gly
            100                 105


<210>  40
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 light chain CDR1

<400>  40

Gly Ala Ser Glu Asn Ile Tyr Gly Ala Leu Asn
1               5                   10


<210>  41
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain CDR2

<400>  41

Gly Ala Ser Asn Leu Ala Asp
1               5


<210>  42 
<211>  10 
<212>  PRT 
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain CDR3

<400>  42

Cys Gln Asn Val Leu Ser Ser Pro Tyr Thr
1               5                   10


<210>  43
<211>  1575
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain

<400>  43
acgcgggaca cagtagtctc tacagtcaca ggagtacaca ggacattgcc atgggttgga      60

gctgtatcat cttctttctg gtagcaacag ctacaggtgt gcactcccag gtccagctgc     120

agcagtctgg gcctgaggtg gtgaggcctg gggtctcagt gaagatttcc tgcaagggtt     180

ccggctacac attcactgat tatgctatgc actgggtgaa gcagagtcat gcaaagagtc     240

tcgagtggat tggacttatt agtacttaca gtggtgatac aaagtacaac cagaatttaa     300

gggcaaggcc acaatgactg tagacaaatc ctccaacaca gcctatatgg aacttgccag     360

attgacatct gaggattctg ccatctatta ctgtgcaaga ggggattatt ccggtagtag     420

gtactggttt gcttactggg gccaagggac tctggtcact gtctctgcag ccaaaacgac     480

acccccatct gtctatccac tggcccctgg atctgctgcc caaactaact ccatggtgac     540

cctgggatgc ctggtcaagg gctatttccc tgagccagtg acagtgacct ggaactctgg     600

atccctgtcc agcggtgtgc acaccttccc agctgttcct gcagtctgac ctctacactc     660

tgagcagctc agtgactgtc ccctccagca cctggcccag cgagaccgtc acctgcaacg     720

ttgcccaccc ggccagcagc accaaggtgg acaagaaaat tgtgcccagg gattgtggtt     780

gtaagccttg catatgtaca gtcccagaag tatcatctgt cttcatcttc cccccaaagc     840

ccaaggatgt gctcaccatt actctgactc ctaaggtcac gtgtgttgtg gtagacatca     900

gcaaggatga tcccgaggtc cagttcagct ggtttgtaga tgatgtggag gtgcacacag     960

ctcagacgca accccgggag gagcagttca acagcacttt ccgctcagtc agtgaacttc    1020

ccatcatgca ccaggactgg ctcaatggca aggagttcaa atgcagggtc aacagtgcag    1080

ctttccctgc ccccatcgag aaaaccatct ccaaaaccaa aggcagaccg aaggctccac    1140

aggtgtacac cattccacct cccaaggagc agatggccaa ggataaagtc agtctgacct    1200

gcatgataac agacttcttc cctgaagaca ttactgtgga gtggcagtgg aatgggcagc    1260

cagcggagaa ctacaagaac actcagccca tcatggacac agatggctct tacttcgtct    1320

acagcaagct caatgtgcag aagagcaact gggaggcagg aaatactttc acctgctctg    1380

tgttacatga gggcctgcac aaccaccata ctgagaagag cctctcccac tctcctggta    1440

aatgatccca gtgtccttgg agccctctgg ccctacagga ctttgacacc tacctccacc    1500

cctccctgta taaataaagc acccagcact gcctcgggac cctgcataaa aaaaaaaaaa    1560

aaaaaaaaaa aaaaa                                                     1575


<210>  44
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain


<220>
<221>  MISC_FEATURE
<222>  (23)..(32)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (47)..(63)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (96)..(107)
<223>  CDR3

<400>  44

Leu Glu Glu Ser Gly Pro Glu Val Val Arg Pro Gly Val Ser Val Lys
1               5                   10                  15


Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr Ala Met His
            20                  25                  30


Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile Gly Leu Ile
        35                  40                  45


Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Asn Gln Asn Phe Lys Gly Lys
    50                  55                  60


Ala Thr Met Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Glu Leu
65                  70                  75                  80


Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Arg Gly
                85                  90                  95


Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala Tyr Trp Gly Gln Gly Thr
            100                 105                 110


Thr Val Thr Arg
        115


<210>  45
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain CDR1

<400>  45

Gly Tyr Thr Phe Thr Asp Tyr Ala Met His
1               5                   10


<210>  46
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain CDR2

<400>  46

Leu Ile Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Asn Gln Asn Phe Lys
1               5                   10                  15


Gly



<210>  47
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain CDR3

<400>  47

Gly Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala Tyr
1               5                   10


<210>  48
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain (ven16C3)

<400>  48

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Gly Ala Ser Glu Asn Ile Tyr Gly Ala
            20                  25                  30


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Gly Ala Ser Asn Leu Ala Asp Gly Met Pro Ser Arg Phe Ser Gly
    50                  55                 60


Ser Gly Ser Gly Arg Gln Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Ser Pro Tyr
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105


<210>  49
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain (cdr16C3)

<400>  49

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Gly Ala Ser Glu Asn Ile Tyr Gly Ala
            20                  25                  30


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Gly Ala Ser Asn Leu Ala Asp Gly Met Pro Ser Arg Phe Ser Gly
    50                  55                  60


Ser Gly Ser Gly Arg Gln Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Ser Pro Tyr
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105


<210>  50
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain (abb16C3)

<400>  50

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Asn Ile Tyr Gly Ala
            20                  25                  30


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Gly Ala Ser Asn Leu Ala Thr Gly Met Pro Ser Arg Phe Ser Gly
    50                  55                  60


Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Ser Pro Tyr
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105


<210>  51
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain (sdr16C3)

<400>  51

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Asn Ile Tyr Gly Ala
            20                  25                  30


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Gly Ala Ser Asn Leu Ala Thr Gly Met Pro Ser Arg Phe Ser Gly
    50                  55                  60


Ser Gly Ser Gly Arg Gln Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Val Leu Ser Ser Pro Tyr
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105


<210>  52
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody light chain (fra16C3)

<400>  52

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Cys Ala Ser Glu Asn Ile Tyr Gly Ala
            20                  25                  30


Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Asn Leu Leu Ile
        35                  40                  45


Tyr Gly Ala Ser Asn Leu Ala Asp Gly Met Pro Ser Arg Phe Ser Gly
    50                  55                  60


Ser Gly Ser Gly Arg Gln Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Ser Pro Tyr
                85                  90                  95


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105


<210>  53
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain (ven16C3)

<400>  53

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Arg Pro Gly Val
1               5                   10                  15


Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30


Ala Met His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile
        35                  40                  45


Gly Leu Ile Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Asn Gln Asn Phe
    50                  55                  60


Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Gly Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala Tyr Trp Gly
            100                 105                 110


Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120


<210>  54
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain (cdr16C3)

<400>  54

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Arg Pro Gly Val
1               5                   10                  15


Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30


Ala Met His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile
        35                  40                  45


Gly Leu Ile Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Asn Gln Asn Phe
    50                  55                  60


Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
                85                  90                  95


Ala Arg Gly Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala Tyr Trp Gly
            100                 105                 110


Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120


<210>  55
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain (abb16C3)

<400>  55

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Arg Pro Gly Val
1                5                  10                  15


Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
             20                 25                  30


Ala Met His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile
        35                  40                  45


Gly Leu Ile Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Ser Gln Lys Phe
    50                  55                  60


Gln Gly Arg Val Thr Met Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Gly Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala Tyr Trp Gly
            100                 105                 110


Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120


<210>  56
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain (sdr16C3)

<400>  56

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Arg Pro Gly Val
1                5                  10                  15


Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30


Ala Met His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile
        35                  40                  45


Gly Leu Ile Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Asn Gln Lys Phe
    50                  55                  60


Gln Gly Lys Ala Thr Met Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Gly Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala Tyr Trp Gly
            100                 105                 110


Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120


<210>  57
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  16C3 antibody heavy chain (fra16C3)

<400>  57

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Arg Pro Gly Val
1               5                   10                  15


Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30


Ala Met His Trp Val Lys Gln Ser His Ala Lys Ser Leu Glu Trp Ile
        35                  40                  45


Gly Leu Ile Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Asn Gln Asn Phe
    50                  55                  60


Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95


Ala Arg Gly Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala Tyr Trp Gly
            100                 105                 110


Gln Gly Thr Leu Val Thr Val Ser Ser
        115                120


<210>  58
<211>  702
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* light chain

<400>  58
atgggcgtgc ccacccagct gctgctgctg tggctgaccg tggtggtggt gcggtgcgac      60

atccagatga cccagtcccc tagctctctg agcgcctccg tgggcgacag ggtgaccatc     120

acctgccaag cctctgagaa catctacggc gccctgaact ggtaccagag gaagcccggc     180

aagagcccca agctgctgat ctacggcgcc tctaacctgg ccaccggcat gcctagccgg     240

ttctccggct ccggcagcgg caccgactac accttcacca tctcctccct gcaacccgag     300

gacatcgcca cctactactg ccagcaggtg ctgtcctccc cctacacctt cggcggcggc     360

accaaactgg agatcaagcg gaccgtggcc gcccccagcg tgttcatctt ccccccctct     420

gacgagcagc tgaagtccgg caccgcctct gtggtgtgcc tgctgaacaa cttctacccc     480

agggaggcca aggtccagtg gaaggtggac aacgccctgc agtccggcaa cagccaggag     540

tctgtgaccg agcaggactc caaggactcc acctacagcc tgtctagcac cctgaccctg     600

tccaaggccg actacgagaa gcacaaggtg tacgcctgcg aggtgaccca ccagggcctg     660

tccagccctg tgaccaagtc cttcaacagg ggcgagtgct ga                        702


<210>  59
<211>  233
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* light chain


<220>
<221>  MISC_FEATURE
<222>  (43)..(53) 
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (69)..(75) 
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (108)..(116)
<223>  CDR3

<400>  59

Met Gly Val Pro Thr Gln Leu Leu Leu Leu Trp Leu Thr Val Val Val
1                5                   10                 15


Val Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
            20                   25                 30


Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Asn Ile
        35                  40                  45


Tyr Gly Ala Leu Asn Trp Tyr Gln Arg Lys Pro Gly Lys Ser Pro Lys
    50                  55                  60


Leu Leu Ile Tyr Gly Ala Ser Asn Leu Ala Thr Gly Met Pro Ser Arg
65                  70                  75                  80


Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser
                85                  90                  95


Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Val Leu Ser
            100                 105                 110


Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr
        115                 120                 125


Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
    130                 135                 140


Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
145                 150                 155                 160


Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
                165                 170                 175


Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
            180                 185                 190


Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
        195                 200                 205


Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
    210                 215                 220


Thr Lys Ser Phe Asn Arg Gly Glu Cys
225                 230


<210>  60
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* light chain CDR1

<400>  60

Gln Ala Ser Glu Asn Ile Tyr Gly Ala Leu Asn
1               5                   10


<210>  61
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* light chain CDR2

<400>  61

Gly Ala Ser Asn Leu Ala Thr
1               5


<210>  62
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* light chain CDR3

<400>  62

Gln Gln Val Leu Ser Ser Pro Tyr Thr
1               5


<210>  63
<211>  1413
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* heavy chain

<400>  63
atgggctggt cctgcatcat cttcttcctg gtggccaccg ccaccggcgt gcacagccag      60

gtgcagcttg tgcagagcgg cgccgaggtg aagaagcccg gcgccagcgt gaaggtgtcc     120

tgcaaggcct ccggctacac cttcaccgac tacgccatgc actgggtgcg gcaggccccc     180

ggccagcggc tggagtggat gggcctgatc agcacctact ctggcgacac caagtacaac     240

cagaacttcc agggccgggt gaccatgacc gtggacaaga gcgccagcac cgcctacatg     300

gagctgtcct ccctgaggtc tgaggacacc gccgtgtact actgcgcccg gggcgactac     360

agcggcagcc ggtactggtt cgcctactgg ggccagggca ccctggtgac cgtgtccagc     420

gcctctacca agggccccag cgtgtttccc ctggcccctt cctccaaaag caccagcggc     480

ggtaccgccg ccctgggctg cctggtgaag gactacttcc ccgagcccgt gaccgtgagc     540

tggaactccg gcgccctgac cagcggcgtg cacaccttcc ctgccgtgct gcaaagctcc     600

ggcctgtact ccctgagctc tgtggtgacc gtgccctcca gctccctggg cacccagacc     660

tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggagcct     720

aagtcttgcg acaagaccca cacctgcccc ccttgccctg cccctgagct gctgggcggc     780

cccagcgtgt tcctgttccc tcccaagccc aaggacaccc tgatgatctc ccggacccct     840

gaggtgacct gcgtggtggt ggatgtgagc cacgaggatc ctgaagtgaa gttcaattgg     900

tatgtggatg gcgtggaggt gcacaacgcc aagaccaagc cccgggagga gcagtacaac     960

agcacctaca gggtggtgtc cgtgctgacc gtgctgcacc aggactggct gaacggcaag    1020

gagtacaagt gcaaggtgtc caacaaggcc ctgcccgccc ccatcgagaa gaccatctcc    1080

aaggccaagg gccagccccg ggagccccag gtgtacaccc tgcctcccag ccgggacgag    1140

ctgaccaaga accaggtgtc cctgacctgc ctggtgaagg gcttctaccc ctctgacatc    1200

gccgtggagt gggagagcaa cggccagccc gagaacaact acaagaccac cccccccgtg    1260

ctggactccg acggctcctt cttcctgtac tctaagctga ccgtggacaa gtcccgctgg    1320

cagcagggca acgtgttcag ctgctccgtg atgcacgagg ccctgcacaa ccactacacc    1380
 
cagaagagcc tgagcctgtc tcccggcaag tga                                 1413


<210>  64
<211>  470
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* heavy chain


<220>
<221>  MISC_FEATURE
<222>  (45)..(54)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (70)..(85) 
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (118)..(129)
<223>  CDR3

<400>  64

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1               5                   10                  15


Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
            20                  25                  30


Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
        35                  40                  45


Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu
    50                  55                  60


Glu Trp Met Gly Leu Ile Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Asn
65                  70                  75                  80

Gln Asn Phe Gln Gly Arg Val Thr Met Thr Val Asp Lys Ser Ala Ser
                85                   90                 95


Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
            100                 105                 110


Tyr Tyr Cys Ala Arg Gly Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala
        115                 120                 125


Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
    130                 135                 140


Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145                 150                 155                 160


Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
                165                 170                 175


Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
            180                 185                 190


Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
        195                 200                 205


Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
    210                 215                 220


Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225                 230                 235                 240


Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
                245                 250                 255


Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
            260                 265                 270


Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
        275                 280                 285


Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
    290                 295                 300


Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305                 310                 315                 320


Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
                325                 330                 335


Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
            340                 345                 350


Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
        355                 360                 365


Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
    370                 375                 380


Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385                 390                 395                 400


Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
                405                 410                 415


Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
            420                 425                 430


Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
        435                 440                 445


Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
    450                 455                 460


Ser Leu Ser Pro Gly Lys
465                 470
 

<210>  65
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* heavy chain CDR1

<400>  65

Gly Tyr Thr Phe Thr Asp Tyr Ala Met His
1                5                  10


<210>  66
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* heavy chain CDR2

<400>  66

Ile Ser Thr Tyr Ser Gly Asp Thr Lys Tyr Asn Gln Asn Phe Gln Gly
1               5                  10                  15


<210>  67
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  h16C3-Abb* heavy chain CDR3

<400>  67

Gly Asp Tyr Ser Gly Ser Arg Tyr Trp Phe Ala Tyr
1               5                  10


<210>  68
<211>  236
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized 31.1 antibody light chain

<400>  68

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1               5                   10                  15


Ala Gln Pro Ala Met Ala Glu Ile Val Met Thr Gln Ser Pro Leu Ser
            20                  25                  30


Leu Pro Val Ser Pro Gly Glu Pro Ala Ser Ile Ser Cys Lys Ala Ser
        35                  40                  45


Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Leu Gln Lys Pro Gly Gln
    50                  55                  60


Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val
65                  70                  75                  80


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
                85                  90                  95


Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Gln Gln
            100                 105                 110


Asp Tyr Ser Ser Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
        115                 120                 125


Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
    130                 135                 140


Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
145                 150                 155                 160


Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
                165                 170                 175


Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
            180                 185                 190


Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
        195                 200                 205


Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
    210                 215                 220


Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225                 230                 235


<210>  69
<211>  467
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized 31.1 antibody heavy chain

<400>  69

Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly
1               5                   10                  15


Ala Gln Ala Gln Val Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys
            20                  25                  30


Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
        35                  40                  45


Thr Asn Tyr Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
    50                  55                  60


Glu Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala
65                  70                  75                  80


Asp Asp Phe Lys Gly Arg Phe Ser Met Ser Leu Asp Thr Ser Thr Ser
                85                  90                  95


Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ser Glu Asp Thr Ala Val
            100                 105                 110


Tyr Phe Cys Ala Arg Ala Tyr Tyr Gly Lys Tyr Phe Asp Tyr Trp Gly
        115                 120                 125


Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
    130                 135                 140


Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
145                 150                 155                 160


Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
                165                 170                 175


Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
            180                 185                 190


Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
        195                 200                 205


Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
    210                 215                 220


Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
225                 230                 235                 240


Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
                245                 250                 255


Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
            260                 265                 270


Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
        275                 280                 285


Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
    290                 295                 300


His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
305                 310                 315                 320


Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
                325                 330                 335


Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
            340                 345                 350


Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
        355                 360                 365


Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
    370                 375                 380


Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
385                 390                 395                 400


Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
                405                 410                 415


Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
            420                 425                 430


Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
        435                 440                 445


His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
    450                 455                 460


Pro Gly Lys 
465


<210>  70
<211>  738
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  humanized NEO 302 light chain

<400>  70
aagcttgcca ccatgaagta cctgctgccc accgctgctg ctggcttgct gctgctggca      60

gctcagcctg ccatggccga gatcgtgatg acccagtccc ctctgtccct gcctgtgtct     120

cctggcgagc ctgcctccat ctcctgcaag gcctcccagt ccgtgtccaa cgacgtggcc     180

tggtatctgc agaagcctgg ccagtccccc aagctgctga tctactacgc ctccaaccgg     240

tacaccggcg tgcccgacag attctccggc tctggctctg gcaccgactt caccctgaag     300

atctcccggg tggaagccga ggacctgggc gtgtactact gtcagcagga ctactcctcc     360

cccctgacct ttggccaggg caccaagctg gaaatcaagc ggaccgtggc cgctccctcc     420

gtgttcatct tcccaccttc cgacgagcag ctgaagtccg gcaccgcttc tgtcgtgtgc     480

ctgctgaaca acttctaccc ccgcgaggcc aaggtgcagt ggaaggtgga caacgccctg     540

cagtccggca actcccagga atccgtgacc gagcaggact ccaaggacag cacctactcc     600

ctgtccagca ccctgaccct gtccaaggcc gactacgaga agcacaaggt gtacgcctgc     660

gaagtgaccc accagggcct gtctagcccc gtgaccaagt ctttcaaccg gggcgagtgc     720

tgatgatgag gatcctga                                                   738


<210>  71
<211>  240
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized NEO 302 light chain

<400>  71

Lys Leu Ala Thr Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu
1               5                   10                  15


Leu Leu Leu Ala Ala Gln Pro Ala Met Ala Glu Ile Val Met Thr Gln
            20                  25                  30


Ser Pro Leu Ser Leu Pro Val Ser Pro Gly Glu Pro Ala Ser Ile Ser
        35                  40                  45


Cys Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Leu Gln
    50                  55                  60


Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Asn Arg
65                  70                  75                  80


Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
                85                  90                  95


Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr
            100                 105                 110


Tyr Cys Gln Gln Asp Tyr Ser Ser Pro Leu Thr Phe Gly Gln Gly Thr
        115                 120                 125


Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
    130                 135                140


Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
145                 150                 155                 160


Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
                165                 170                 175


Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln
            180                 185                 190


Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
        195                 200                 205


Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His
    210                 215                 220


Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225                 230                 235                 240


<210>  72
<211>  1431
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  humanized NEO 302 heavy chain

<400>  72
aagcttgcca ccatggactg gacctggcgc atcctgtttc tggtggccgc tgctacaggc      60

gcccaggctc aggtgcagct ggtgcagtct ggacccgagc tgaagaaacc tggcgcctcc     120

gtgaaggtgt cctgcaaggc ttccggctac acctttacca actacggcat gaactgggtg     180

cgacaggccc ctggcaaggg cctggaatgg atgggctgga tcaacaccta caccggcgag     240

cccacctacg ccgacgactt caagggccgg ttctccatgt ccctggacac ctccaccagc     300

accgcctacc tgcagatctc cagcctgaag tccgaggata ccgccgtgta cttctgcgcc     360

agagcctact acggcaagta cttcgactac tggggccagg gcaccctcgt gaccgtgtcc     420

tctgcttcta ccaagggccc ctccgtgttc cctctggccc cttccagcaa gtctacctct     480

ggcggcacag ccgctctggg ctgcctcgtg aaggactact tccccgagcc cgtgacagtg     540

tcttggaact ctggcgccct gacctccggc gtgcacacct ttccagctgt gctgcagtcc     600

tccggcctgt actccctgtc ctccgtcgtg actgtgccct ccagctctct gggcacccag     660

acctacatct gcaacgtgaa ccacaagccc tccaacacca aggtggacaa gaaggtggaa     720

cccaagtcct gcgacaagac ccacacctgt cccccttgtc ctgcccctga actgctgggc     780

ggacccagcg tgttcctgtt ccccccaaag cccaaggaca ccctgatgat ctcccggacc     840

cccgaagtga cctgcgtggt ggtggatgtg tctcacgagg accctgaagt gaagttcaat     900

tggtacgtgg acggcgtgga agtgcacaac gccaagacca agcctagaga ggaacagtac     960

aactccacct accgggtggt gtccgtgctg accgtgctgc accaggattg gctgaacggc    1020

aaagagtaca agtgcaaggt gtccaacaag gccctgcctg cccccatcga aaagaccatc    1080

tccaaggcca agggccagcc ccgggaaccc caggtgtaca cactgccccc tagcagggac    1140

gagctgacca agaaccaggt gtccctgacc tgtctcgtga aaggcttcta cccctccgat    1200

atcgccgtgg aatgggagtc caacggccag cctgagaaca actacaagac caccccccct    1260

gtgctggact ccgacggctc attcttcctg tacagcaagc tgacagtgga caagtcccgg    1320

tggcagcagg gcaacgtgtt ctcctgctcc gtgatgcacg aggccctgca caaccactac    1380

acccagaagt ccctgtccct gagccccggc aagtgatgat gaggatcctg a             1431


<210>  73
<211>  471
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized NEO 302 heavy chain

<400>  73

Lys Leu Ala Thr Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala
1               5                   10                  15


Ala Ala Thr Gly Ala Gln Ala Gln Val Gln Leu Val Gln Ser Gly Pro
            20                  25                  30


Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
        35                  40                  45


Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn Trp Val Arg Gln Ala Pro
    50                  55                  60


Gly Lys Gly Leu Glu Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu
65                  70                  75                  80


Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ser Met Ser Leu Asp
                85                  90                  95


Thr Ser Thr Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ser Glu
            100                 105                 110


Asp Thr Ala Val Tyr Phe Cys Ala Arg Ala Tyr Tyr Gly Lys Tyr Phe
        115                 120                 125


Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
    130                 135                 140


Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
145                 150                 155                 160


Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
                165                 170                 175


Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
            180                 185                 190


Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
        195                 200                 205


Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
    210                 215                 220


Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
225                 230                 235                 240


Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
                245                 250                 255


Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
            260                 265                 270


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
        275                 280                 285


Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
    290                 295                 300

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
305                 310                 315                 320


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
                325                 330                 335


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
            340                 345                 350


Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
        355                 360                 365


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
    370                 375                 380


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
385                 390                 395                 400


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
                405                 410                 415


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
            420                 425                 430


Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
        435                 440                 445


Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
    450                 455                 460


Leu Ser Leu Ser Pro Gly Lys
465                 470


<210>  74
<211>  448
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain (cdr31.1)


<220>
<221>  MISC_FEATURE
<222>  (1)..(118)
<223>  Variable region

<220>
<221>  MISC_FEATURE
<222>  (25)..(35) 
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(70)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (99)..(108) 
<223>  CDR3

<400>  74

Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
        35                  40                  45


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
    50                  55                  60


Lys Gly Arg Phe Ala Phe Thr Leu Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys
                85                  90                  95


Ala Arg Ala Tyr Tyr Gly Lys Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110


Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
        115                 120                 125


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
    130                 135                 140


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145                 150                 155                 160


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                165                 170                 175


Ser Ser Gly Pro Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
            180                 185                 190


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
        195                 200                 205


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
    210                 215                 220


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
225                 230                 235                 240


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
                245                 250                 255


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
            260                 265                 270


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
        275                 280                 285


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
    290                 295                 300


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
305                 310                 315                 320


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
                325                 330                 335


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
            340                 345                 350


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
        355                 360                 365


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
    370                 375                 380


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Met Pro Pro Val Leu Asp
385                 390                 395                 400


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
                405                 410                 415


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
            420                 425                 430


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445


<210>  75
<211>  448
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain (abb31.1)


<220>
<221>  MISC_FEATURE
<222>  (1)..(118)
<223>  Variable region

<220>
<221>  MISC_FEATURE
<222>  (25)..(35)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(70) 
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (99)..(108) 
<223>  CDR3

<400>  75

Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30


Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
        35                  40                  45


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gln Lys Phe
    50                  55                  60


Gln Gly Arg Val Thr Phe Thr Leu Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                   80


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys
                85                  90                  95


Ala Arg Ala Tyr Tyr Gly Lys Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110


Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
        115                 120                 125


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
    130                 135                 140


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145                 150                 155                 160


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                165                 170                 175


Ser Ser Gly Pro Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
            180                 185                 190


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
        195                 200                 205


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
    210                 215                 220


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
225                 230                 235                 240


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
                245                 250                 255


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
            260                 265                 270


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
        275                 280                 285


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
    290                 295                 300


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
305                 310                 315                 320


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
                325                 330                 335


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
            340                 345                 350


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
        355                 360                 365


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
    370                 375                 380


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Met Pro Pro Val Leu Asp
385                 390                 395                 400


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
                405                 410                 415


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
            420                 425                 430


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445


<210>  76
<211>  448
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain (sdr31.1)

<220>
<221>  MISC_FEATURE
<222>  (1)..(118)
<223>  Variable region

<220>
<221>  MISC_FEATURE
<222>  (25)..(35) 
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(70) 
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (99)..(108) 
<223>  CDR3

<400>  76

Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30


Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
        35                  40                  45


Gly Trp Ile Asn Pro Tyr Thr Gly Glu Pro Thr Tyr Ala Gln Lys Phe
    50                  55                  60


Gln Gly Arg Val Thr Phe Thr Leu Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys
                85                  90                  95


Ala Arg Ala Tyr Tyr Gly Lys Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110


Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
        115                 120                 125


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
    130                 135                 140


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145                 150                 155                 160


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                165                 170                 175


Ser Ser Gly Pro Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
            180                 185                 190


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
        195                 200                 205


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
    210                 215                 220


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
225                 230                 235                 240


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
                245                 250                 255


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
            260                 265                 270


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
        275                 280                 285


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
    290                 295                 300


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
305                 310                 315                 320


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
                325                 330                 335


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
            340                 345                 350


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
        355                 360                 365


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
    370                 375                 380


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Met Pro Pro Val Leu Asp
385                 390                 395                 400


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
                405                 410                 415


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
            420                 425                 430


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445


<210>  77
<211>  448
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain (ven31.1)


<220>
<221>  MISC_FEATURE
<222>  (1)..(118)
<223>  Variable region

<220>
<221>  MISC_FEATURE
<222>  (25)..(35) 
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(70) 
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (99)..(108)
<223>  CDR3

<400>  77

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala
1               5                   10                  15


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30


Gly Met Asn Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Lys Trp Met
        35                  40                  45


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
    50                  55                  60


Lys Gly Arg Phe Ala Phe Thr Leu Asp Thr Ser Ile Ser Thr Ala Tyr
65                  70                  75                  80


Leu Glu Ile Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys
                85                  90                  95


Ala Arg Ala Tyr Tyr Gly Lys Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110


Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
        115                 120                 125


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
    130                 135                 140


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
145                 150                 155                 160


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
                165                 170                 175


Ser Ser Gly Pro Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
            180                 185                 190


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
        195                 200                 205


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
    210                 215                 220


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
225                 230                 235                 240


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
                245                 250                 255


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
            260                 265                 270


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
        275                 280                 285


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
    290                 295                 300


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
305                 310                 315                 320


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
                325                 330                 335


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
            340                 345                 350


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
        355                 360                 365


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
    370                 375                 380


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Met Pro Pro Val Leu Asp
385                 390                 395                 400


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
                405                 410                 415


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
            420                 425                 430


Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445


<210>  78
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain CDR1

<400>  78

Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn
1               5                   10


<210>  79
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain CDR2

<400>  79

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys
1               5                   10                  15


Gly Arg Phe Ala Phe
            20


<210>  80
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain CDR2

<400>  80

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Gln Lys Phe Gln
1               5                   10                  15


Gly Arg Val Thr Phe
            20


<210>  81
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain CDR2

<400>  81

Trp Ile Asn Pro Tyr Thr Gly Glu Pro Thr Tyr Ala Gln Lys Phe Gln
1               5                   10                  15


Gly Arg Val Thr Phe
            20


<210>  82
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain CDR2

<400>  82

Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys
1               5                   10                  15


Gly Arg Phe Ala Phe
            20


<210>  83
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody Heavy Chain CDR3

<400>  83

Ala Tyr Tyr Gly Lys Tyr Phe Asp Tyr Trp
1               5                   10


<210>  84
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain (cdr31.1)

<220>
<221>  MISC_FEATURE
<222>  (1)..(107)
<223>  Variable region

<220>
<221>  MISC_FEATURE
<222>  (21)..(34)
<223> CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(56)
<223> CDR2

<220>
<221>  MISC_FEATURE
<222>  (89)..(97)
<223>  CDR3

<400>  84

Ser Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
            20                  25                  30


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
    50                  55                  60


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Leu
                85                  90                  95


Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
            100                 105                 110


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
        115                 120                 125


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
    130                 135                 140


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145                 150                 155                 160


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
                165                 170                 175


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
            180                 185                 190


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
        195                 200                 205

Phe Asn Arg Gly Glu Cys 
    210


<210>  85
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain (abb31.1)


<220>
<221>  MISC_FEATURE
<222>  (1)..(107)
<223>  Variable region

<220>
<221>  MISC_FEATURE
<222>  (21)..(34)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(56)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (89)..(97)
<223>  CDR3

<400>  85

Ser Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Asn Asp
            20                  25                  30


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Tyr Ala Ser Asn Arg Tyr Ser Gly Val Pro Asp Arg Phe Ser Gly
    50                  55                  60


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Leu
                85                  90                  95


Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
            100                 105                 110


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
        115                 120                 125


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
    130                 135                 140


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145                 150                 155                 160


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
                165                 170                 175


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
            180                 185                 190


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
        195                 200                 205

Phe Asn Arg Gly Glu Cys 
    210


<210>  86
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain (sdr31.1)


<220>
<221>  MISC_FEATURE
<222>  (1)..(107)
<223>  Variable region

<220>
<221>  MISC_FEATURE
<222>  (21)..(34)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(56)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (89)..(97)
<223>  CDR3

<400>  86

Ser Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asp
            20                  25                  30


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
    50                  55                  60


Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65                  70                  75                  80


Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Leu
                85                  90                  95


Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
            100                 105                 110 


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
        115                 120                 125


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
    130                 135                 140


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145                 150                 155                 160


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
                165                 170                 175


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
            180                 185                 190


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
        195                 200                 205


Phe Asn Arg Gly Glu Cys
    210


<210>  87
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain (ven31.1)


<220>
<221>  MISC_FEATURE
<222>  (1)..(107)
<223>  Variable region

<220>
<221>  MISC_FEATURE
<222>  (21)..(34)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(56)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (89)..(97)
<223>  CDR3

<400>  87

Ser Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Val Gly
1               5                   10                  15


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp
            20                  25                  30


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
        35                  40                  45


Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
    50                  55                  60


Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Pro
65                  70                  75                  80


Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Leu
                85                  90                  95


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala
            100                 105                 110


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
        115                 120                 125


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
    130                 135                 140


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145                 150                 155                 160


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
                165                 170                 175


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
            180                 185                 190


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
        195                 200                 205


Phe Asn Arg Gly Glu Cys
    210


<210>  88
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain CDR1

<400>  88

Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala
1               5                   10


<210>  89
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain CDR1

<400>  89

Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Asn Asp Val Ala
1               5                   10


<210>  90
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain CDR1

<400>  90

Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asp Leu Ala
1               5                   10


<210>  91
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain CDR2

<400>  91

Tyr Ala Ser Asn Arg Tyr Thr
1               5


<210>  92
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain CDR2

<400>  92

Tyr Ala Ser Asn Arg Tyr Ser
1               5


<210>  93
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NEO-303 antibody light chain CDR3

<400>  93

Gln Gln Asp Tyr Ser Ser Pro Leu Thr
1               5



<210>  94
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  31.1 epitope

<400>  94

Ser Pro Thr Pro Gln Tyr Ser Trp Lys Arg Tyr Asn Ile Leu Asn Gln
1               5                   10                  15


Glu Gln Pro


